Investigational drug · Phase 3
PRV111
Also called: Cisplatin Transmucosal System
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Oral Squamous Cell Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PRV111"
First trial start
2024
Nov 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRV111", any sponsor or status.
Conditions studied
As listed on its trial records.
- Oral Squamous Cell Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "PRV111" as an intervention, largest first.
- A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung CancersPivotal-lookingRecruiting
Privo TechnologiesIndustry
NCT05893888 · 40 participants (planned) · Start Nov 7, 2024 · Primary completion Oct 2026
Drug: PRV211 (Intraoperative Cisplatin System); PRV111 (Cisplatin Transmucosal System) and 1 more · For: Oral Squamous Cell Carcinoma
Sites: Duarte, California; Miami, Florida; Chicago, Illinois · 4 sites in all
Privo TechnologiesIndustry
NCT03502148 · 10 participants · Start Jun 19, 2018 · Primary completion Oct 27, 2019
Drug: PRV111 (Cisplatin Transmucosal System) · For: Oral Squamous Cell Carcinoma
Sites: Louisville, Kentucky; Cincinnati, Ohio; Houston, Texas · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer.
Goldberg M, Manzi A, Birdi A, et al. · Nat Commun 2022
Also in development for Oral Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.